Mechanisms of resistance to noncovalent Bruton Tyrosine Kinase inhibitors is delineated
16435
post-template-default,single,single-post,postid-16435,single-format-standard,bridge-core-1.0.4,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.0.9,qode-theme-bridge,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-5.7,vc_responsive
 

Mechanisms of resistance to noncovalent Bruton Tyrosine Kinase inhibitors is delineated

Home > Blogs  > Mechanisms of resistance to noncovalent Bruton Tyrosine Kinase inhibitors is delineated

11 Mar Mechanisms of resistance to noncovalent Bruton Tyrosine Kinase inhibitors is delineated

Posted at 10:45h in Blogs by

The mechanisms of resistance to noncovalent (reversible) BTK inhibitors was not fully known. Genomic analyses of pre and post-treatment samples from patients with CLL treated with the non-covalent BTK inhibitor pirtobrutinib showed that resistance to noncovalent BTK inhibitors arose through on-target BTK mutations and downstream PLCγ2 mutations. This data suggests new mechanisms of genomic escape from established covalent and novel noncovalent BTK inhibitors. (Ref: Wang E et al.NEJM, 2022)

https://www.linkedin.com/feed/update/urn:li:activity:6907962121779597312

No Comments

Sorry, the comment form is closed at this time.